Clearside Biomedical (CLSD)
(Real Time Quote from BATS)
$1.14 USD
+0.01 (0.89%)
Updated Jul 23, 2024 03:16 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLSD 1.14 +0.01(0.89%)
Will CLSD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for CLSD
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
Clearside Biomedical to host KOL event on July 24
Disney, MicroStrategy initiated: Wall Street's top analyst calls